A phase II Clinical Study of CP-4055 as second line therapy in patients with advanced colorectal cancer
收藏NIAID Data Ecosystem2026-03-06 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/2521306
下载链接
链接失效反馈官方服务：
资源简介：
Primary objectives: To evaluate the objective tumour response in patients with advanced colorectal cancer when treated with CP-4055 for infusion D1-5/4w.
Primary endpoints: Tumour response defined as Complete Response (CR) and/or Partial Response (PR), characterized by measuring the target lesions, and according to the RECIST criteria.The Response Rate (= PR + CR) will be estimated and a 95 % confidence interval calculated.
创建时间：
2007-03-15
